Last reviewed · How we verify
NCT06855017: ROSA
Writing: a Factor That Can Influence Understanding of Prescriptions in the Geriatric Population
trial testing create a pillbox day in Prescription Medication Understanding in 64 participants. Completed in 11 June 2025.
11 June 2025
Quick facts
| Lead sponsor | Assistance Publique - Hôpitaux de Paris |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 64 |
| Start date | 12 August 2024 |
| Primary completion | 11 June 2025 |
| Estimated completion | 11 June 2025 |
| Sites | 1 location across France |
Drugs / interventions tested
- create a pillbox day
Conditions studied
- Prescription Medication Understanding — all drugs for Prescription Medication Understanding →
Sponsor
Assistance Publique - Hôpitaux de Paris — full company profile →
Who can join
75 and older, any sex, with Prescription Medication Understanding. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Understanding prescriptions is a key factor in the therapeutic education and compliance of elderly patients with multiple medications. However, the way prescriptions are written and typed depends on doctors' habits, due to a lack of recommendations on the subject. The introduction of a state-qualified nurse to manage treatment will soon be a public health issue, given the ageing population and human resources problems. The hypothesis is that certain editorial and typographical choices can make prescriptions clearer, and could thus help elderly patients, either cognitively unaffected or at risk of cognitive fragility, to better understand their prescriptions and thus limit the risk of medication errors.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06855017
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Assistance Publique - Hôpitaux de Paris trials
Trials by the same sponsor.
- NCT07443436 — Immunomodulatory Treatment of Interstitial Lung Disease Associated With Surfactant Related Gene Variants · Phase 2 · not yet recruiting
- NCT07499492 — Red Blood Cell Transfusion to Optimize Extubation · NA · not yet recruiting
- NCT07379918 — Real-life Evaluation of Endopredict® in Early HR+/HER2- Breast Cancer · recruiting
- NCT07473869 — Smartphone Application for Automated Measurement of Capillary Refill Time (CRT) · not yet recruiting
- NCT07505394 — Efficacy of a Prediction Model-based Algorithm to PREVENT Drug-induced Impulse Control Disorders in Parkinson's Disease · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06855017 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Assistance Publique - Hôpitaux de Paris
- Last refreshed: 8 January 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06855017.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing